Transfer of long-lasting tumor immunity by immune T cells from MHC congenic mice: migration, survival and tumor-protectivity of cytotoxic donor cells.
Immunocompetent B10.D2 (H-2d) mice are able to reject the highly malignant lymphoma ESb of DBA/2 (H-2d) origin very effectively. Seven days after intravenous injection of the ESb tumor cells, B10.D2 mice developed a strong tumor-rejection response which was associated with the generation of anti-tumor T cells in their spleens with direct cytotoxic activity. Most of the cytotoxic potential was directed against the minor histocompatibility differences as demonstrated by the lysis of unrelated DBA/2 derived Eb tumor cells and normal DBA/2 but no B10.D2 derived ConA lymphoblasts. A previously performed clonal analysis, however, revealed a minority population of CTL clones which specifically recognized the ESb specific transplantation antigen (ESb-TATA). When transferred systemically into DBA/2 mice, the B10.D2 anti-ESb immune spleen cells could delay the outgrowth of s.c. transplanted ESb tumor cells. When the ESb tumor cells were experimentally distributed in a s.c. implanted sponge-matrix, the i.v. injected B10.D2 immune cells could confer complete protective immunity against the metastatic tumor, provided the recipients were pre-treated with 5 Gy to allow a better take of the allogeneic cells. The distribution of intravenously injected B10.D2 donor spleen cells was assessed in the recipients up to 50 days by cytotoxicity testing and assaying for the expression of the beta 2 microglobulin allelic form b (beta 2mb). These tests revealed a high propensity of donor cells to populate the spleen and lymph nodes of the DBA/2 recipients. Again this was particularly marked in sublethally irradiated mice where a long-lasting lymphoid chimerism was established.
Zangemeister-Wittke
U
U
Institute for Immunology and Genetics, German Cancer Research Center, Heidelberg.
Schirrmacher
V
V
D000818:Animals; D000951:Antigens, Neoplasm / Q000276:immunology; D002634:Chemotaxis, Leukocyte; D005260:Female; D006084:Graft Rejection; D006183:H-2 Antigens / Q000276:immunology; D007121:Immunocompetence; D016219:Immunotherapy, Adoptive; D008223:Lymphoma / Q000276:immunology / Q000628:therapy*; D051379:Mice; D008810:Mice, Inbred C57BL / Q000276:immunology; D008811:Mice, Inbred DBA / Q000276:immunology; D009368:Neoplasm Transplantation; D011828:Radiation Chimera; D013154:Spleen / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology / Q000637:transplantation*; D001613:beta 2-Microglobulin / Q000276:immunology
D000951:Antigens, Neoplasm; D006183:H-2 Antigens; D001613:beta 2-Microglobulin